Precision medicine in pancreatic cancer involves biomarker testing to identify specific genetic alterations (e.g., mutations in BRCA1/2, PALB2) that guide treatment decisions, targeted therapies that specifically target molecular abnormalities (e.g., PARP inhibitors for patients with BRCA mutations), and leveraging immunotherapies based on individual immune profiles [34,35]. Here, PALB2 is linked to pancreatic neoplasm.